Clinical trial
Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
NCT00006483 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00006483 |
|---|---|
| Title | Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung |
| Official title | A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Metastatic Cancer |
| Intervention type | Biological |
| Interventions | sargramostim |
| Enrollment | 27 |
| Start date | Oct 1, 2000 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2013 |
| First posted | Apr 29, 2004 |
| Last update posted | Jul 13, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: